Prostate-specific antigen and prostate volume: a meta-analysis of prostate cancer screening criteria.
KEY WORDS: Free
prostate-specific antigen; Prostate; carcinoma.
The digital rectal exam,
prostate-specific antigen and transrectal echography in the diagnosis of prostatic cancer.
Structure, function, and regulation of the enzyme activity of
prostate-specific antigen. World J Urol 1993; 11 (4): 188-191.
Associations of demographic and lifestyle characteristics with
prostate-specific antigen (PSA) concentration and rate of PSA increase.
Prostate-specific antigen and prostate cancer: prediction, detection and monitoring.
Prostate-Specific Antigen (PSA) is a blood marker that can enable very early detection of the most common cancer striking men, thereby enabling curative therapies to be employed before metastasis strikes.
The second Danish study, also led by Dr Orsted, looked at whether
prostate-specific antigen levels could predict prostate cancer incidence and mortality in the general population.
Further,
prostate-specific antigen density (PSAD), the ratio of the serum to the size of the prostate calculated as total serum PSA divided by prostate volume has also been correlated as an improvement to total PSA for the prostate can-cer.
Reference range of
prostate-specific antigen after transurethral resection of the prostate.
Research released last week from the journal Cancer showed that for those with the lowest baseline levels of
prostate-specific antigen, or PSA, 24,642 men would have to be screened and 724 cases of prostate cancer would have to be treated to prevent one death.
Results of a Swedish study suggest that screening with the
prostate-specific antigen (PSA) blood test may help reduce deaths from prostate cancer almost by half over 14 years.